Fluocinonide (Topical)

Fluocinonide (Topical) is a topical corticosteroid (class of steroid hormones formed in the adrenal gland ). Fluocinonide (Topical) is used to reduce swelling or inflammation and itching of skin in conditions such as psoriasis, eczema, dermatitis, rashes, insect bites, and allergies etc.

Brands
Adult Dose
Dose: 0.05%
Single Dose: 0.05 (0.05)
Frequency: As recommended.
Route: Topical
Instructions: As Required
Neonatal
Dose: 0.05%
Single Dose: 0.05 (0.05)
Frequency: As recommended.
Route: Topical
Instructions: As Required
Paedriatic
Dose: 0.05%
Single Dose: 0.05 (0.05)
Frequency: As recommended.
Route: Topical
Instructions: As Required
Characteristics
. It is of Synthetic origin and belongs to Corticosteroid. It belongs to Glucocorticoid agonist pharmacological group on the basis of mechanism of action and also classified in Dermatological Products and Corticosteroid Topical pharmacological group.The Molecular Weight of Fluocinonide (Topical) is 494.50. Its pKa is unionized.
Contraindications
Fluocinonide (Topical) is contraindicated in conditions like Bacterial infections,Fungal infection,Viral infection,Ulcers,Acne vulgaris,Rosacea,Perioral dermatitis.
Effects
The severe or irreversible adverse effects of Fluocinonide (Topical), which give rise to further complications include Telangiectasia, Striae, Glaucoma, Cataract, Growth retardation, Adrenal suppression, Epidermal thinning, Raised intracranial pressure.The symptomatic adverse reactions produced by Fluocinonide (Topical) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Allergic reactions, Perioral dermatitis.
Indications
Fluocinonide (Topical) is primarily indicated in conditions like Dermatitis, Eczema, Flexural psoriasis, Lichen planus, Lichen simplex, Lupus erythematosus, Necrobiosis lipoidica, Pruritus ANI.
Interactions
No data regarding the interactions of Fluocinonide (Topical) was found.
Interfrence
ACTH Stimulation testUrinary free cortisol testACTH stimulation test
Risks
Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Topical Soln, Cream, Oint, Gel Store Below 40°C. Do not Freeze. Protect from Sunlight.
Warnings
Fluocinonide should be used with caution in patients with active tuberculosis infection of respiratory tract or in untreated fungal, bacterial or systemic viral infections. Corticosteroids should only be used systemically with great caution in the presence of congestive heart failure (CHF), recent myocardial infraction (MI), hypertension, diabetes mellitus, epilepsy, glaucoma, hypothyroidism, liver failure, osteoporosis, peptic ulceration or renal impairment. Children may be at increase risk of some adverse effects, corticosteroid causes growth retardation and prolonged use is rarely justified. Passive immunization is recommended to non-immune patients who do come in contact with chickenpox or measles. Live vaccine should not be given to patients receiving high dose systemic corticosteroid therapy nor for atleast 3months afterwards, killed vaccine or toxoids may be given, although the response may be attenuated. During prolong treatment with corticosteroids, patients should be examined regularly, sodium intake may need to be reduced and calcium and potassium supplement may be necessary. Patient should carry cards given full details of their corticosteroid therapy. Avoid use during pregnancy. Use nasal steroids with caution until healing has occurred.
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.